Complete financial analysis of Altamira Therapeutics Ltd. (CYTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altamira Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rainbow Digital Commercial Co., Ltd. (002419.SZ) Income Statement Analysis – Financial Results
- Top KingWin Ltd (WAI) Income Statement Analysis – Financial Results
- Hansae Yes24 Holdings Co., Ltd (016450.KS) Income Statement Analysis – Financial Results
- Synthomer plc (SYNT.L) Income Statement Analysis – Financial Results
- First Avenue for Real Estate De (9610.SR) Income Statement Analysis – Financial Results
Altamira Therapeutics Ltd. (CYTO)
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 305.62K | 63.88K | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.44M | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.14M | -2.18M | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -372.44% | -3,407.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.04M | 19.68M | 8.94M | 2.86M | 3.33M | 6.69M | 19.21M | 24.78M | 26.54M | 17.70M | 13.25M | 3.99M |
| General & Administrative | 3.09M | 3.52M | 4.90M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Selling & Marketing | 15.35K | 2.38M | 1.50M | 95.66K | 113.96K | 43.82K | 199.48K | 45.65K | 72.56K | 237.72K | 479.03K | 86.23K |
| SG&A | 3.12M | 5.90M | 6.39M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Other Expenses | 0.00 | -586.73K | -409.93K | 0.00 | 0.00 | 215.72K | 87.59K | 34.06K | 62.20K | 73.43K | 49.42K | 34.28K |
| Operating Expenses | 6.54M | 24.99M | 14.92M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Cost & Expenses | 6.54M | 26.44M | 17.16M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Interest Income | 730.20K | 969.00 | 3.22K | 258.00 | 17.88K | 0.00 | 53.57K | 67.57K | 37.00K | 52.13K | 74.04K | 5.83K |
| Interest Expense | 0.00 | 911.87K | 189.70K | 135.15K | 28.63K | 1.07M | 1.64M | 828.55K | 8.00K | 49.64K | 50.18K | 0.00 |
| Depreciation & Amortization | 5.92M | 118.89K | 76.36K | 20.04K | 30.82K | 72.71K | 122.78K | 97.60K | 92.78K | 73.98K | 37.52K | 9.24K |
| EBITDA | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M | -10.95M | -24.31M | -30.06M | -30.84M | -22.19M | -14.51M | -4.60M |
| EBITDA Ratio | 0.00% | -8,511.54% | -26,643.21% | -3,027.89% | 12,930.83% | -865.25% | -7,548.97% | 7,260.41% | 46,031.34% | -737.55% | 0.00% | 0.00% |
| Operating Income | -5.92M | -26.13M | -17.10M | -5.28M | -7.26M | -10.95M | -24.36M | -30.22M | -30.88M | -22.19M | -14.62M | -4.61M |
| Operating Income Ratio | 0.00% | -8,550.76% | -26,767.78% | -3,028.04% | 12,962.76% | -865.25% | -7,565.61% | 7,300.31% | 46,086.57% | -737.59% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.35M | -645.64K | -1.46M | -2.94M | 433.41K | -380.10K | -66.00K | -570.03K | 1.17M | 4.01M | -82.89K | 8.09K |
| Income Before Tax | -7.27M | -26.54M | -17.37M | -8.22M | -6.83M | -11.33M | -24.43M | -30.79M | -29.71M | -18.19M | -14.70M | -4.60M |
| Income Before Tax Ratio | 0.00% | -8,683.69% | -27,188.48% | -4,712.11% | 12,188.82% | -895.28% | -7,586.10% | 7,438.00% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.33K | 21.62K | -21.28K | -193.84K | 162.18K | -17.77K | -131.06K | -84.78K | -892.18K | 305.75K | 0.00 |
| Net Income | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M | -11.50M | -24.41M | -30.66M | -29.71M | -18.19M | -15.00M | -4.60M |
| Net Income Ratio | 0.00% | -8,680.31% | -27,222.33% | -4,699.91% | 11,842.68% | -908.09% | -7,580.58% | 7,406.34% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| EPS | -14.81 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| EPS Diluted | -14.80 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| Weighted Avg Shares Out | 491.00K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
| Weighted Avg Shares Out (Dil) | 491.26K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will be presenting at the 2 nd Annual mRNA-Based Therapeutics Summit Europe...
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic non-small...
Hydrogel Dressing (Amorphous Hydrogel, Impregnated Hydrogel) Market Size, Share & Trends Analysis Report 2022-2030 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Hydrogel Dressing Market Size, Share & Trends Analysis Report by Product (Amorphous Hydrogel, Impregnated Hydrogel), by Application (Acute Wounds, Chronic Wounds), by End Use (Hospitals, Specialty Clinics), by Region, and Segment Forecasts, 2022-2030" report has been added to...
CytoImmune Therapeutics to Present Preclinical Data Highlighting Potential of Novel TRACK-NK Cells to Selectively Target and Kill Hematologic and Solid Tumor Cancer Cells
MONROVIA, Calif.--(BUSINESS WIRE)--CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced new preclinical data highlighting the potential of the company’s tumor-reactive NK (TRACK-NK) cell program, CYTO-102, to...
10 Top Penny Stocks To Buy For Uner $1 Right Now
Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Altamira Therapeutics (CYTO) Stock Up 70% Today?
Apparently, biotechnology firm Altamira Therapeutics (NASDAQ: CYTO ) would prefer to concentrate on its RNA delivery business. So, the company is divesting its subsidiary that focuses on inner-ear development.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from an interim analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results...
Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study
Altamira Therapeutics Ltd (NASDAQ: CYTO) announced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic rhinitis. The HDM challenge trial demonstrated a statistically significant reduction of nasal symptoms vs.
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it is scheduled to present virtually at the H.C.
Altamira Therapeutics Ltd. (CYTO) CEO Thomas Meyer on Q4 2021 Results - Earnings Call Transcript
Altamira Therapeutics Ltd. (CYTO) CEO Thomas Meyer on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports